NanoViricides, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NNVC NYSE American 2830 www.nanoviricides.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NanoViricides, Inc.

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial - Jul 28th, 2026 6:30 am
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - Jul 24th, 2026 6:00 am
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - Jul 22nd, 2026 6:30 am
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo - Jul 13th, 2026 7:27 am
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - Jul 8th, 2026 6:30 am
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Jul 6th, 2026 11:27 am
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - Jul 6th, 2026 6:30 am
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher - Jun 29th, 2026 6:30 am
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Jun 25th, 2026 7:00 am
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - Jun 22nd, 2026 7:30 am
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo - Jun 15th, 2026 6:30 am
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies - Jun 8th, 2026 6:30 am
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - May 26th, 2026 6:30 am
NanoViricides closes $2M direct offering - May 19th, 2026 7:06 am
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - May 18th, 2026 9:55 pm
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - May 18th, 2026 6:34 am
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides - May 18th, 2026 6:30 am
NanoViricides to raise $2M in registered direct offering - May 15th, 2026 8:02 am
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - May 15th, 2026 6:35 am
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II - May 15th, 2026 6:00 am